

**PHARMANUTRA S.P.A. OBTAINS APPROVAL FOR TWO NEW PATENTS
IN INDIA AND UNITED STATES**

The Group obtains approval of the Cetilar® patent in the USA and new prospects unfold for SiderAL® in India thanks to a new patent linked to the Sucrosomial® Technology being granted. Expansion continues in Europe where a new agreement is stipulated with the Bulgarian company, Naturpharma.

Pisa, 25th March 2020 – PharmaNutra S.p.A. (Aim Italia -Ticker PHN), pharmaceutical company leader in the iron-based nutritional supplements market and already present in 50 countries, announces that it has obtained **two new assets, strategic** for the Group's international expansion. **Two patents** have been approved **in India and the United States respectively** - markets with considerable potential given their size - to further strengthen the foreign presence of the Tuscan company founded by the Lacorte brothers.

For what concerns **India**, the patent approved is for **“Solid Iron” (number 328725)** and will expire in 2033. The patent refers to the SiderAL® trademark line, created thanks to the innovative Sucrosomial® Technology that has enabled the PharmaNutra flagship products to overcome the limits and problems caused by administration of oral iron, a mineral with reduced absorption and low gastrointestinal tolerability. This unique, patented action mechanism has enabled PharmaNutra supplements to gain a foothold as the most effective and innovative in the sector. So much so, that for the latest market IQVIA data formalised by FederSalus, SiderAL® Forte 20 capsules is the nutritional supplement that sells most in Italy.

The second patent concerns Cetilar®, the product line studied to reduce the painful post-trauma symptoms in muscles and joints, now officially recognised on the US market. Approval of the new **Cetilar® patent (number US10,597,608, approved on 24-3-2020) in the USA** will last until 2036 and is a fundamental step forwards in the spread of a brand that in Italy - also thanks to a number of top level sports partnerships - has acquired a solid reputation.

The Cetilar® brand will also be present in **Bulgaria**, thanks to a **recent agreement** finalised by PharmaNutra S.p.A. with Naturpharma, a company founded in 1997 and constantly on the lookout for innovative products for the Bulgarian market.

“India and the United States are two of the most important key markets globally. The fact that local authorities have officially acknowledged the value of our patents is a significant step forwards for the PharmaNutra Group”, the President, Andrea Lacorte declares. “However, our scientific research continues non-stop as we are encouraged to improve and take PharmaNutra science to an even higher level”.

PharmaNutra S.p.A.

Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. The efficacy of the products has been demonstrated with a wealth of scientific evidence, with 112 studies published involving more than 7000 subjects. The Group distributes and sells its products in Italy and abroad. In Italy, products are sold through a network of 140 Pharmaceutical Representatives serving doctors and also exclusively selling PharmaNutra products to pharmacies throughout Italy. Products are sold in over 50 countries abroad, through 34 partners selected from among the finest pharmaceutical companies. PharmaNutra leads the market in the production of iron-based nutritional supplements under the SiderAL® brand, where it boasts a number of important patents on Sucrosomial® technology. Over the years, the Group has developed a precise strategy for the management and production of intellectual property, founded on the integrated management of all the various elements: proprietary raw materials, patents, brands and clinical evidence.

PharmaNutra.it

For Information:

PharmaNutra S.p.A.

Via Delle Lenze, 216/b
56122 Pisa
Tel. +39 050 7846500
investorrelation@pharmanutra.it
Internal Press Office
press@calabughi.com

Nomad

CFO SIM S.p.A.

Via dell'Annunciata, 23/4
20121 Milan
Tel. +39 02 303431
ecm@cfosim.com

Press Office

Spriano Communication & Partners

Via Santa Radegonda, 16
20121 Milan
Tel. +39 02 83635708

Matteo Russo
mrusso@sprianocommunication.com
Cristina Tronconi
ctronconi@sprianocommunication.com